Abvc Biopharma (ABVC) Assets Average (2011 - 2026)

Abvc Biopharma (ABVC) has reported Assets Average for 14 consecutive years, with $19.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 73.57% year-over-year to $19.6 million; the trailing twelve-month figure through Jun 2026 stood at $19.6 million (up 73.57% YoY), and the FY2025 full-year result was $14.3 million, up 86.64% from the prior year.
• Assets Average fell to $19.6 million in Q2 2026 per ABVC's latest filing, from $20.4 million in the prior quarter.
• Across five years, Assets Average topped out at $21.1 million in Q4 2025 and bottomed at $7.6 million in Q4 2023.
• Historically, Assets Average has averaged $11.9 million across 5 years, with a median of $10.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Assets Average sank 31.09% in 2023, then soared 176.0% in 2025.
• Over 5 years, Assets Average stood at $10.0 million in 2022, then declined by 24.31% to $7.6 million in 2023, then increased by 0.88% to $7.7 million in 2024, then jumped by 176.0% to $21.1 million in 2025, then declined by 7.43% to $19.6 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $19.6 million, $20.4 million, and $21.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.